TR-1: Standard form for notification of major holdings To view notification click here
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce subscriptions and a placing to raise £3.55 million (the “Subscription(s)” and “Placing”) through the issue of 32,272,727 new ordinary shares of 10 pence each in the Company (“Ordinary Shares”) at a price of 11 pence per Ordinary Share (“Issue…
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is very pleased to announce that it has signed a 2-year collaboration agreement with Imperial College London. Under the collaboration, Imperial College will provide significant intellectual input and guidance on a number of innovative peptide assets being developed at our R&D subsidiary, ImmuPharma Biotech in Bordeaux.…
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to present a comprehensive and detailed update of the significant positive progress achieved since major changes in the Board and Senior Management re-structuring in August 2021. Key highlights Lupuzor™ PK study on track to deliver results in Q1 2022 and to move into…
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, provides an update on its delisting from the Euronext Growth Brussels market, where it has a dual listing with AIM. This proposed de-listing from Euronext Growth Brussels was recently confirmed in the Company’s ‘Corporate Update’ announcement on 29 September 2021. The…
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is delighted to announce that Prof. Sylviane Muller, inventor of Lupuzor™ and P140 technology and a key collaboration partner, has been awarded the highly prestigious Legion d’honneur Award. The ‘Remise des insignes d’officier de la Légion d’honneur’ was presented to Prof.…
ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is pleased to provide an update in respect to a number of corporate and scientific activities within the business over the last period. Introduction Following the major change in our managerial and Board structure over the last couple of months, the…
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2021 (the “Period”). Key Highlights (including post Period review) Financials Financial performance in line with expectations over the Period Cash balance of £4.2m as…
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that each member of the Board of Directors and PDMR, Ewa Flynn (Chief Financial Officer) have on 23 & 24 August 2021 purchased in total 670,000 ordinary shares of 10p in the Company (“Ordinary Shares”). Details of the share purchases…
TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS To download click here